Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Quince Therapeutics (QNCX) will participate in two investor conferences in September 2026. The company’s senior management will join a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026 at 2:45 p.m. ET, and will provide a company presentation at the H.C. Wainwright 28th Annual Global Investment Conference starting September 14, 2026. Webcasts and replays of both events will be available through the Investors section of Quince’s website.
Quince Therapeutics (Nasdaq: QNCX) reported second quarter 2026 results highlighting the completed stock‑for‑stock acquisition of Orphai Therapeutics, adding lead asset LAM‑001, an inhaled rapamycin for multiple serious pulmonary diseases. Concurrently, the company closed a private placement with $115 million in gross upfront proceeds and potential for up to an additional $83 million upon warrant exercise.
Cash and cash equivalents were $116 million as of June 30, 2026, which Quince expects will fund operations through year‑end 2028. R&D expense was $5.5 million versus $6.6 million a year earlier, while G&A rose to $16.6 million, driven by non‑cash stock‑based compensation and higher professional fees. Net loss was $75.5 million, or $12.31 per share, compared with a $16.0 million loss in the prior‑year quarter. Quince advanced LAM‑001 into Phase 2b PH‑ILD and continued a Phase 2 BOS trial, supported by Phase 2a data showing clinically meaningful improvements in six‑minute walk distance and pulmonary vascular resistance.
Quince Therapeutics (Nasdaq: QNCX) formed a Scientific Advisory Board to guide development of LAM-001, an inhaled rapamycin (mTOR inhibitor) targeting multiple serious pulmonary indications, including PH-ILD, BOS, and SAPH.
The SAB includes internationally recognized leaders in pulmonary vascular disease, advanced lung disease, lung transplantation, and sarcoidosis, who have led pivotal clinical trials and major research programs in these areas.
Quince Therapeutics (Nasdaq: QNCX) announced settlement of its European Investment Bank loan obligations effective March 27, 2026. The company paid $5.5 million to fully satisfy approximately $16.4 million of outstanding EIB debt, enabling restructuring and evaluation of strategic alternatives.
Management says the settlement removes a substantial overhang that constrained flexibility and supports pursuit of merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics (Nasdaq: QNCX) engaged LifeSci Capital as its exclusive financial advisor on February 9, 2026 to evaluate strategic alternatives and assist with restructuring of the company’s liabilities.
Options under review may include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions; the company will not comment further until the Board approves any specific action.
Quince Therapeutics (Nasdaq: QNCX) reported topline results from the pivotal Phase 3 NEAT trial of eDSP in Ataxia-Telangiectasia. The trial (n=105) failed to meet the primary RmICARS endpoint (difference -1.30; p=0.0851) and a key secondary CGI-S endpoint (p=0.522).
eDSP was generally well tolerated with no clinically meaningful safety concerns. The company will cease clinical development of eDSP and intends to preserve cash while exploring available options.
Quince Therapeutics (NASDAQ: QNCX) presented previously published safety data on long-term eDSP in children with Ataxia-Telangiectasia at the British Paediatric Neurology Association Annual Meeting, Glasgow, January 28-30, 2026.
Key highlights: stable height and weight z-scores, no corticosteroid-related growth suppression or weight gain, no adrenal insufficiency confirmed, and no glucose homeostasis concerns; routine monitoring recommended.
Quince Therapeutics (Nasdaq: QNCX) announced the last patient last visit in its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) for Ataxia-Telangiectasia (A-T).
The company enrolled 105 participants (83 in the 6–9 year primary cohort; 22 aged ≥10), executed the study under a Special Protocol Assessment, and reports low discontinuation rates and an independent data safety monitoring board that met three times with no safety concerns. Quince expects to report topline results in the middle of Q1 2026. Most participants (all but one) transitioned to an open-label extension.
Quince Therapeutics (Nasdaq: QNCX) announced publication in Frontiers in Drug Delivery summarizing eight early-stage clinical trials of its lead asset eDSP (dexamethasone sodium phosphate encapsulated in autologous red blood cells) in pulmonary and inflammatory bowel disorders.
Key findings: eDSP was dosed every two weeks or monthly across ages 5–83, produced improved FEV1 and fewer infections in cystic fibrosis, improved COPD symptoms with lower steroid exposure, enabled corticosteroid withdrawal in 60%–78% of IBD patients, and showed DSP levels persisting up to 28 days post-infusion; mean infusion dose did not exceed 10 mg.
Quince Therapeutics (Nasdaq: QNCX) announced senior management will participate in three investor events in December 2025: a Piper Sandler fireside chat on Dec 3, 2025 at 10:30 AM ET, a panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, and a virtual Lunch with LifeSci fireside chat on Dec 16, 2025 at 1:00 PM ET. Presenters include Dirk Thye, M.D. (CEO & CMO), Charles Ryan, J.D., Ph.D. (President), and Brendan Hannah (COO & CBO). The Piper Sandler and LifeSci sessions will be webcast with archives available, and the Oppenheimer panel highlights near-term catalysts as Quince advances toward pivotal Phase 3 NEAT topline results expected in Q1 2026.